-
-
-
-
-
-
-
Halozyme adds biotech executive Appelhans to its board
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
-
-
-
-
-
-
-
Halozyme names David Ramsay as interim CFO effective March 23
-
-
-
-
-
-
-
Jim Lang Elected to Halozyme's Board of Directors
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $92 at Citizens on Strong Quarter
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
-
-
-
-
-
-
-
Firms face COVID-level uncertainty amid Trump tariffs - Morgan Stanley
-
1,231,050 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


